Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis
Chunteng Jiang,Santuan Xie,Guang Yang,Ningning Wang
DOI: https://doi.org/10.2147/JIR.S344730
IF: 4.5
2021-12-21
Journal of Inflammation Research
Abstract:Chunteng Jiang, 1, 2 Santuan Xie, 1 Guang Yang, 3 Ningning Wang 3 1 Department of Internal Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, People's Republic of China; 2 Department of Cardiology and Pneumology, University Medical Center of Göttingen, Georg-August-University of Göttingen, Göttingen, Lower Saxony, Germany; 3 Department of Food Nutrition and Safety, School of Public Health, Dalian Medical University, Dalian, Liaoning, People's Republic of China Correspondence: Guang Yang; Ningning Wang Email ; Inflammation is an intricate biological response of body tissues to detrimental stimuli. Cardiovascular disease (CVD) is the leading cause of death worldwide, and inflammation is well documented to play a role in the development of CVD, especially atherosclerosis (AS). Emerging evidence suggests that activation of the NOD-like receptor (NLR) family and the pyridine-containing domain 3 (NLRP3) inflammasome is instrumental in inflammation and may result in AS. The NLRP3 inflammasome acts as a molecular platform that triggers the activation of caspase-1 and the cleavage of pro-interleukin (IL)-1β, pro-IL-18, and gasdermin D (GSDMD). The cleaved GSDMD forms pores in the cell membrane and initiates pyroptosis, inducing cell death and the discharge of intracellular pro-inflammatory factors. Hence, the NLRP3 inflammasome is a promising target for anti-inflammatory therapy against AS. In this review, we systematically summarized the current understanding of the activation mechanism of NLRP3 inflammasome, and the pathological changes in AS involving NLRP3. We also discussed potential therapeutic strategies targeting NLRP3 inflammasome to combat AS. Keywords: cardiovascular disease, atherosclerosis, NLRP3 inflammasome, mechanisms, therapeutic strategies Cardiovascular disease (CVD) remains the dominant causal factor of mortality globally in spite of tremendous improvements in therapy and efficacy. 1 Atherosclerosis (AS) is a leading cause of CVD, resulting in approximately 50% of deaths throughout the world. Four pathologic changes are considered to be associated with atherogenesis: (1) endothelial injury; (2) deposition of lipoproteins in the vessel wall; (3) adhesion, migration, and differentiation of monocytes into macrophages and formation of foam cells; (4) proliferation and migration of smooth muscle cells (SMCs). 2 Notably, inflammatory response of these cells is the common basis for the physiopathologic changes throughout the initiation and progression of AS. It is now generally assumed that inflammatory processes and lipid metabolism work together in the formation of atherosclerotic plaques (Figure 1). 3 Figure 1 Schematic of atherogenesis. Risk factors such as high cholesterol, hyperglycemia, and smoking are contributors of atherogenesis. These activators gain access to the intima via damaged endothelial cells (ECs). Damaged ECs trigger NLRP3 inflammasome activation, IL-1β and IL-18 release, thus further leading to inflammation. On the other hand, damaged ECs express adhesion molecules that capture the monocytes, which get into the intima and differentiate into macrophages. Macrophages ingest lipid and turn into foams cells, which gradually die and release their contents (such as IL-1β and IL-18), giving rise to the inflammatory response. The inflammatory response stimulates the migration and proliferation of smooth muscles cells (SMCs), which aggregate in the plaques to form fibroproliferative lesions. Inflammation is a complex physiological and pathological process by which the body struggles to respond to injury and infection, as mediated by constituents of the innate immune system. The innate immune system acts as the first line of defense against non-self and danger signals from microbial invasion and tissue damage, and plays a central role in acute host defense. These danger signals can be recognized by pattern recognition receptors (PRRs), which are extensively expressed on the surface or in the cytosol in numerous types of cells, such as monocytes, macrophages, neutrophils, mast cells, dendritic cells, and natural killer cells. There are at least five groups of PRRs, including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (NLRs), retinoic acid-inducible gene-I-like receptors (RLRs), C-type lectin receptors (CLRs), and absent-in-melanoma (AIM)-like receptors (ALRs). 4 These activated PRRs subsequently oligomerize and assemble large multi-subunit complexes to activate signaling cascades that stimulate the recruitment of inflammatory mediators to eliminate pathogens, infected cells or tissues. 5,6 Two types of molecular patterns can be identified by PRRs, including pathogen -Abstract Truncated-
immunology